Native Valve Endocarditis due toCandida glabrataTreated without Valvular Replacement: A Potential Role for Caspofungin in the Induction and Maintenance Treatment
Open Access
- 1 October 2004
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (7) , e70-e73
- https://doi.org/10.1086/424018
Abstract
Conventional antifungal therapy for fungal endocarditis has been associated with a poor cure rate. Therefore, combined medical and surgical therapy hKeywords
This publication has 14 references indexed in Scilit:
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicansJournal of Antimicrobial Chemotherapy, 2003
- CaspofunginDrugs, 2003
- Comparison of Caspofungin and Amphotericin B for Invasive CandidiasisNew England Journal of Medicine, 2002
- Antifungal Susceptibility ofCandidaBiofilms: Unique Efficacy of Amphotericin B Lipid Formulations and EchinocandinsAntimicrobial Agents and Chemotherapy, 2002
- Nosocomial cardiac infectionsJournal of Hospital Infection, 2002
- Late Recurrent Candida EndocarditisChest, 1991
- Sensitive bioassay for ketoconazole in serum and cerebrospinal fluidAntimicrobial Agents and Chemotherapy, 1981
- The role of valve replacement in the treatment of fungal endocarditisThe Journal of Thoracic and Cardiovascular Surgery, 1975
- Tissue Penetration of Amphotericin B in Candida EndocarditisChest, 1974